SCHEDULE: Invus-Affiliated Entities Disclose 5.4% Stake in Rezolute
Beneficial Ownership Report
Raymond Debbane and affiliated entities, including Invus Public Equities and Avicenna Life Sci Master Fund, reported beneficial ownership of 5.4% of Rezolute, Inc.'s common stock.
Summary
- Raymond Debbane, through various affiliated entities, beneficially owns 4,870,000 shares of Rezolute, Inc. common stock.
- This aggregate ownership represents 5.4% of Rezolute's outstanding common stock, based on 90,811,368 shares as of September 15, 2025.
- Invus Public Equities, L.P. directly holds 4,171,401 shares, representing 4.6% of the class.
- Avicenna Life Sci Master Fund LP directly holds 698,599 shares, representing 0.8% of the class.
- Invus Public Equities Advisors, LLC, Invus Global Management, LLC, and Siren, L.L.C. are control persons over Invus Public Equities, L.P.
- Avicenna Life Sci Master GP LLC and Ulys, L.L.C. are control persons over Avicenna Life Sci Master Fund LP.
- Raymond Debbane is the managing member of Siren, L.L.C. and Ulys, L.L.C., and thus controls all the reported shares.
- The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of Rezolute, Inc., except for activities solely related to a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, with no explicit positive or negative implications for the company's operations or financial health. The certification disclaiming intent to influence control maintains a neutral stance.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding Rezolute, Inc.'s future operations or financial performance.
Industry Context
This filing is a standard disclosure of beneficial ownership by institutional investors and an individual, indicating their passive investment in Rezolute, Inc. It does not provide specific insights into broader industry trends or competitive positioning.
Key Dates
| Date | Description |
|---|---|
| 2025-09-15 | Date of outstanding shares calculation for Rezolute, Inc. (90,811,368 shares). |
| 2025-09-17 | Date Rezolute, Inc. filed its Annual Report on Form 10-K, reporting outstanding shares. |
| 2025-09-18 | Date of event requiring the filing of this Schedule 13G. |
| 2025-09-22 | Date of signing of the Schedule 13G filing and Joint Filing Agreement. |
Keywords
Rezolute Inc., RZLT, Schedule 13G, Beneficial Ownership, Invus Public Equities, Avicenna Life Sci Master Fund, Raymond Debbane, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.